spacer
home > > spring 2002 > drug information association's 14th annual euromeeting - basel, switzerland, 5th-8th march 2002
PUBLICATIONS


Drug Information Association's 14th Annual EuroMeeting - Basel, Switzerland, 5th-8th March 2002

The 14th annual DIA EuroMeeting is based on the premise that in the 21st Century only a relatively small proportion of all diseases can be adequately treated, nevermind cured. At a fundamental level there is a lack of understanding of the mechanism of disease - particularly the genetic basis of disease and its implications for rational drug treatment.

Of equal concern is that only a small proportion of all patients have access to safe medicinal products at affordable prices. The availability of safe and effective medicines is a real issue in third world countries where for many patients the cost of diagnosis and treatment are beyond their means. This leads to counterfeit and often dangerous substitutes being sold in those countries. Where treatments are available there is often a lack of clear information on the products and their rational use.

Regulatory authorities, government health departments and medical insurance companies add their own particular and specific hurdles to the early availability of effective treatments.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Richard Barrett of Pfizer Global Research and Development, UK

Richard Barrett of Pfizer Global Research and Development, UK is the Co-Chairperson of the Euro2002 Programme Committee, along with Manuel Zahn, of AstraZeneca, Sweden.
spacer
Richard Barrett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IMFINZITM (durvalumab) WITH CHEMOTHERAPY DEMONSTRATED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN THE PHASE III CASPIAN TRIAL

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement